The protective effect of tumor necrosis factor-alpha inhibitors in COVID-19 in patients with inflammatory rheumatic diseases compared to the general population-A comparison of two German registries
Copyright © 2024 Hasseli, Hanses, Stecher, Specker, Weise, Borgmann, Hasselberger, Hertenstein, Hower, Hoyer, Koll, Krause, von Lilienfeld-Toal, Lorenz, Merle, Nunes de Miranda, Pletz, Regierer, Richter, Rieg, Roemmele, Ruethrich, Schmeiser, Schulze-Koops, Strangfeld, Vehreschild, Voit, Voll, Vehreschild, Müller-Ladner and Pfeil..
Objectives: To investigate, whether inflammatory rheumatic diseases (IRD) inpatients are at higher risk to develop a severe course of SARS-CoV-2 infections compared to the general population, data from the German COVID-19 registry for IRD patients and data from the Lean European Survey on SARS-CoV-2 (LEOSS) infected patients covering inpatients from the general population with SARS-CoV-2 infections were compared.
Methods: 4310 (LEOSS registry) and 1139 cases (IRD registry) were collected in general. Data were matched for age and gender. From both registries, 732 matched inpatients (LEOSS registry: n = 366 and IRD registry: n = 366) were included for analyses in total.
Results: Regarding the COVID-19 associated lethality, no significant difference between both registries was observed. Age > 65°years, chronic obstructive pulmonary disease, diabetes mellitus, rheumatoid arthritis, spondyloarthritis and the use of rituximab were associated with more severe courses of COVID-19. Female gender and the use of tumor necrosis factor-alpha inhibitors (TNF-I) were associated with a better outcome of COVID-19.
Conclusion: Inflammatory rheumatic diseases (IRD) patients have the same risk factors for severe COVID-19 regarding comorbidities compared to the general population without any immune-mediated disease or immunomodulation. The use of rituximab was associated with an increased risk for severe COVID-19. On the other hand, the use of TNF-I was associated with less severe COVID-19 compared to the general population, which might indicate a protective effect of TNF-I against severe COVID-19 disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Frontiers in medicine - 11(2024) vom: 19., Seite 1332716 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Revised 22.03.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3389/fmed.2024.1332716 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370000374 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370000374 | ||
| 003 | DE-627 | ||
| 005 | 20240323001520.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240322s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fmed.2024.1332716 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1341.xml |
| 035 | |a (DE-627)NLM370000374 | ||
| 035 | |a (NLM)38510457 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hasseli, Rebecca |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The protective effect of tumor necrosis factor-alpha inhibitors in COVID-19 in patients with inflammatory rheumatic diseases compared to the general population-A comparison of two German registries |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 22.03.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2024 Hasseli, Hanses, Stecher, Specker, Weise, Borgmann, Hasselberger, Hertenstein, Hower, Hoyer, Koll, Krause, von Lilienfeld-Toal, Lorenz, Merle, Nunes de Miranda, Pletz, Regierer, Richter, Rieg, Roemmele, Ruethrich, Schmeiser, Schulze-Koops, Strangfeld, Vehreschild, Voit, Voll, Vehreschild, Müller-Ladner and Pfeil. | ||
| 520 | |a Objectives: To investigate, whether inflammatory rheumatic diseases (IRD) inpatients are at higher risk to develop a severe course of SARS-CoV-2 infections compared to the general population, data from the German COVID-19 registry for IRD patients and data from the Lean European Survey on SARS-CoV-2 (LEOSS) infected patients covering inpatients from the general population with SARS-CoV-2 infections were compared | ||
| 520 | |a Methods: 4310 (LEOSS registry) and 1139 cases (IRD registry) were collected in general. Data were matched for age and gender. From both registries, 732 matched inpatients (LEOSS registry: n = 366 and IRD registry: n = 366) were included for analyses in total | ||
| 520 | |a Results: Regarding the COVID-19 associated lethality, no significant difference between both registries was observed. Age > 65°years, chronic obstructive pulmonary disease, diabetes mellitus, rheumatoid arthritis, spondyloarthritis and the use of rituximab were associated with more severe courses of COVID-19. Female gender and the use of tumor necrosis factor-alpha inhibitors (TNF-I) were associated with a better outcome of COVID-19 | ||
| 520 | |a Conclusion: Inflammatory rheumatic diseases (IRD) patients have the same risk factors for severe COVID-19 regarding comorbidities compared to the general population without any immune-mediated disease or immunomodulation. The use of rituximab was associated with an increased risk for severe COVID-19. On the other hand, the use of TNF-I was associated with less severe COVID-19 compared to the general population, which might indicate a protective effect of TNF-I against severe COVID-19 disease | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a general population | |
| 650 | 4 | |a inflammatory rheumatic diseases | |
| 650 | 4 | |a severe disease | |
| 650 | 4 | |a tumor necrosis factor-alpha inhibitors | |
| 700 | 1 | |a Hanses, Frank |e verfasserin |4 aut | |
| 700 | 1 | |a Stecher, Melanie |e verfasserin |4 aut | |
| 700 | 1 | |a Specker, Christof |e verfasserin |4 aut | |
| 700 | 1 | |a Weise, Tobias |e verfasserin |4 aut | |
| 700 | 1 | |a Borgmann, Stefan |e verfasserin |4 aut | |
| 700 | 1 | |a Hasselberger, Martina |e verfasserin |4 aut | |
| 700 | 1 | |a Hertenstein, Bernd |e verfasserin |4 aut | |
| 700 | 1 | |a Hower, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Hoyer, Bimba F |e verfasserin |4 aut | |
| 700 | 1 | |a Koll, Carolin |e verfasserin |4 aut | |
| 700 | 1 | |a Krause, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a von Lilienfeld-Toal, Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Lorenz, Hanns-Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Merle, Uta |e verfasserin |4 aut | |
| 700 | 1 | |a Nunes de Miranda, Susana M |e verfasserin |4 aut | |
| 700 | 1 | |a Pletz, Mathias W |e verfasserin |4 aut | |
| 700 | 1 | |a Regierer, Anne C |e verfasserin |4 aut | |
| 700 | 1 | |a Richter, Jutta G |e verfasserin |4 aut | |
| 700 | 1 | |a Rieg, Siegbert |e verfasserin |4 aut | |
| 700 | 1 | |a Roemmele, Christoph |e verfasserin |4 aut | |
| 700 | 1 | |a Ruethrich, Maria M |e verfasserin |4 aut | |
| 700 | 1 | |a Schmeiser, Tim |e verfasserin |4 aut | |
| 700 | 1 | |a Schulze-Koops, Hendrik |e verfasserin |4 aut | |
| 700 | 1 | |a Strangfeld, Anja |e verfasserin |4 aut | |
| 700 | 1 | |a Vehreschild, Maria J G T |e verfasserin |4 aut | |
| 700 | 1 | |a Voit, Florian |e verfasserin |4 aut | |
| 700 | 1 | |a Voll, Reinhard E |e verfasserin |4 aut | |
| 700 | 1 | |a Vehreschild, Jörg Janne |e verfasserin |4 aut | |
| 700 | 1 | |a Müller-Ladner, Ulf |e verfasserin |4 aut | |
| 700 | 1 | |a Pfeil, Alexander |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in medicine |d 2014 |g 11(2024) vom: 19., Seite 1332716 |w (DE-627)NLM245390847 |x 2296-858X |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2024 |g day:19 |g pages:1332716 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fmed.2024.1332716 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2024 |b 19 |h 1332716 | ||